CD274 and colitis: Recent data from a phase I trial examining m7824, a bispecific agent targeting PD-L1 and TGFΒ in advanced solid tumors, revealed TRAEs of grade ≥ 3 in 21.1% of participants, encompassing conditions such as skin infections, asymptomatic lipase elevation, colitis coupled with anemia, and gastroparesis accompanied by hypokalemia [20].